NBTY Agrees To $2.1M Settlement With FTC For False DHA Claims
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission's ongoing crackdown on "bogus" health claims leads to a $2.1 million settlement with NBTY and two subsidiaries to resolve charges they overstated the amount and benefit of DHA in children's multivitamins.
You may also be interested in...
In Brief
J&J names pharma vet to lead McNeil
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
Omega-3 Probe Underscores FTC Standard For Claims Substantiation
FTC's widespread review of omega-3 fatty acid supplement claims reminds firms they must support claims with "competent and reliable scientific evidence," a standard stakeholders argue is unclear and at times impractical